Citation Impact
Citing Papers
Lectin‐like oxidized low density lipoprotein receptor‐1 (LOX‐1) serves as an endothelial receptor for advanced glycation end products (AGE)
2002
The RAGE Axis
2010
RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response
2002
RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy
2003
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions
2004
Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients
2008
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
2007
Diabetic retinopathy
2010 Standout
Inflammation and metabolic disorders
2006 StandoutNature
FEEL-1 and FEEL-2 Are Endocytic Receptors for Advanced Glycation End Products
2003
Advanced glycation and endothelial functions: A link towards vascular complications in diabetes
2004
Advanced Glycation End Products-Induced Gene Expression of Scavenger Receptors in Cultured Human Monocyte-Derived Macrophages
2000
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
2000 StandoutNature
The biology of the receptor for advanced glycation end products and its ligands
2000
Increased oxidative stress in obesity and its impact on metabolic syndrome
2004 Standout
The biology of RAGE and its ligands: Uncovering mechanisms at the heart of diabetes and its complications
2007
N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression
1999
Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study
2009
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
2002 StandoutNature
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice
2003
Oxycodone for neuropathic pain and fibromyalgia in adults
2014
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
2006
Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
2013
Hallmarks of aging: An expanding universe
2023 Standout
Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system
2003
Juvenile idiopathic arthritis
2007 Standout
Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
2016 Standout
Pathological Roles of Advanced Glycation End Product Receptors SR‐A and CD36
2005
Non-specific low back pain
2016 Standout
Atherosclerosis and diabetes: The rage connection
2000
A Role for the Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis
2008
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
2008
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model
2001
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
2001
How hyperglycemia promotes atherosclerosis: molecular mechanisms
2002
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes
2005
Expression of Advanced Glycation End Products and Their Cellular Receptor RAGE in Diabetic Nephropathy and Nondiabetic Renal Disease
2000
Nonresolving Inflammation
2010 Standout
Osteoarthritis
2015 Standout
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Inflammation and insulin resistance
2006 Standout
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α
2007
Receptor for Advanced Glycation End Products, Inflammation, and Accelerated Periodontal Disease in Diabetes: Mechanisms and Insights Into Therapeutic Modalities
2001
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
2001
Soluble form of a receptor for advanced glycation end products sRAGE as a biomarker
2010
Non-alcoholic fatty liver disease
2021 Standout
Drug Overdose in a Retrospective Cohort with Non-Cancer Pain Treated with Opioids, Antidepressants, and/or Sedative-Hypnotics: Interactions with Mental Health Disorders
2015
Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis
2005
SGLT2 Inhibitors in Liver Patients
2020
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
A New Perspective on Therapeutic Inhibition of Advanced Glycation in Diabetic Microvascular Complications: Common Downstream Endpoints Achieved Through Disparate Therapeutic Approaches?
2009
Diabetes and Atherosclerosis
2002 Standout
The Role of Oxidative Stress in Diabetic Complications
2005
Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice
2000
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation
2009
Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes
2009
The Economic Burden of Opioid-Related Poisoning in the United States
2013
Scavenger receptors for oxidized and glycated proteins
2003
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice
2005
RAGE: A New Target for the Prevention and Treatment of the Vascular and Inflammatory Complications of Diabetes
2000
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease
2001
Oxidants, oxidative stress and the biology of ageing
2000 StandoutNature
Inflammation in atherosclerosis
2002 StandoutNature
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
2004
Blockade of Receptor for Advanced Glycation End-Products Restores Effective Wound Healing in Diabetic Mice
2001
Origin and physiological roles of inflammation
2008 StandoutNature
Advanced Glycation Urinary Protein-Bound Biomarkers and Severity of Diabetic Nephropathy in Man
2011
Biochemistry and molecular cell biology of diabetic complications
2001 StandoutNature
Key Role of Src Kinase in S100B-induced Activation of the Receptor for Advanced Glycation End Products in Vascular Smooth Muscle Cells
2006
The RAGE Axis and Endothelial Dysfunction: Maladaptive Roles in the Diabetic Vasculature and Beyond
2005
Proinflammatory S100 proteins in arthritis and autoimmune disease
2004
Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy
2005
Idiopathic pulmonary fibrosis
2011 Standout
Atherosclerosis
2000 StandoutNature
Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases
2008
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Exploring the full spectrum of macrophage activation
2008 Standout
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy
2003
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
Involvement of Microglial Receptor for Advanced Glycation Endproducts (RAGE) in Alzheimer's Disease: Identification of a Cellular Activation Mechanism
2001
Molecular Mechanisms of Amyloidosis
2003 Standout
Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways
1999
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells
2003
Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes
2006 Standout
RAGE Mediates a Novel Proinflammatory Axis
1999 Standout
Evidence Supporting a Role for Endoplasmic Reticulum Stress in the Development of Atherosclerosis in a Hyperglycaemic Mouse Model
2009
A Qualitative Study of Veterans on Long-Term Opioid Analgesics: Barriers and Facilitators to Multimodality Pain Management
2014
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes
2008
Chronic Vascular Inflammation in Patients With Type 2 Diabetes
2005
Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products
2004
Advanced glycation end products activate Smad signaling via TGF‐β‐dependent and ‐independent mechanisms: implications for diabetic renal and vascular disease
2003
Advanced Glycation End Products
2006 Standout
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
Diabetes Accelerates Smooth Muscle Accumulation in Lesions of Atherosclerosis
2001
Alternative splicing of the murine receptor for advanced glycation end‐products (RAGE) gene
2009
Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
2004
The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells
2001
Glycation, Inflammation, and RAGE
2003
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
2000
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury
2003
The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins
2003
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation
2000
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
2005 Standout
Identification, classification, and expression of RAGE gene splice variants
2007
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
2016 Standout
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions
2004
Immune and Inflammatory Mechanisms of Atherosclerosis
2009
RAGE: a novel biological and genetic marker for vascular disease
2009
Inflammation and Atherosclerosis
2002 Standout
RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice
2002
RAGE Regulates the Metabolic and Inflammatory Response to High-Fat Feeding in Mice
2014
Genetic Modifiers of Atherosclerosis in Mice
2000
Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes
2010
Stochastic non-enzymatic modification of long-lived macromolecules - A missing hallmark of aging
2020
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
2001
Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice
2001
Synthesis of an organoinsulin molecule that can be activated by antibody catalysis
2001 StandoutNobel
Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes
2015
Activation of Receptor for Advanced Glycation End Products
1999
Mechanisms of Diabetic Complications
2013 Standout
Understanding RAGE, the receptor for advanced glycation end products
2005
Effects of Intensive Glucose Lowering in Type 2 Diabetes
2008 Standout
Glucosamine-Induced Endoplasmic Reticulum Dysfunction Is Associated With Accelerated Atherosclerosis in a Hyperglycemic Mouse Model
2006
Thiazolidinediones Reduce Endothelial Expression of Receptors for Advanced Glycation End Products
2004
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
2016 Standout
Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis
2004
Adenoviral transfer of HIF-1α enhances vascular responses to critical limb ischemia in diabetic mice
2009 StandoutNobel
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response
2004 Standout
S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules
2006
Advanced Glycosylation End Products Up-Regulate Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein-Related Protein 2) in Human Fibroblasts: A Potential Mechanism for Expansion of Extracellular Matrix in Diabetes Mellitus*
2001
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Opioids compared to placebo or other treatments for chronic low-back pain
2013
The RAGE Axis in Early Diabetic Retinopathy
2005
Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells.
2000
Osteoarthritis: an update with relevance for clinical practice
2011 Standout
Oral Infection With a Periodontal Pathogen Accelerates Early Atherosclerosis in Apolipoprotein E–Null Mice
2003
Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice
2002
Free Radicals in the Physiological Control of Cell Function
2002 Standout
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
2013
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
2002 Standout
INFLAMMATION AND ATHEROSCLEROSIS
2006
Treatment of Periodontitis and Endothelial Function
2007 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
RAGE Axis
2004
Works of Wing Chow being referenced
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes
2006
Rationale and design of the Oxycodone Users Registry: A prospective, multicenter registry of patients with nonmalignant pain
2013
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
2018
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
1998
Clinicians' Attitudes and Beliefs About Opioids Survey (CAOS): Instrument Development and Results of a National Physician Survey
2013
Reported side effects, bother, satisfaction, and adherence in patients taking hydrocodone for non-cancer pain
2013
Elevated Circulating Adipocyte‐Fatty Acid Binding Protein Levels Predict Incident Cardiovascular Events in a Community‐Based Cohort: A 12‐Year Prospective Study
2013
Opioid Shopping Behavior: How Often, How Soon, Which Drugs, and What Payment Method
2012
Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production
2007
Circulating Levels of Adipocyte and Epidermal Fatty Acid–Binding Proteins in Relation to Nephropathy Staging and Macrovascular Complications in Type 2 Diabetic Patients
2008